Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo observacional, multicêntrico, prospectivo e do mundo real para HPN na China (ReWoPNH)

22 de setembro de 2026 atualizado por: AstraZeneca

Um estudo observacional, multicêntrico, prospectivo e do mundo real para hemoglobinúria paroxística noturna (HPN) na China

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Visão geral do estudo

Status

Concluído

Condições

Descrição detalhada

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Tipo de estudo

Observacional

Inscrição (Real)

724

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Hangzhou, China
        • Research Site
    • Anhui
      • Hefei, Anhui, China, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100000
        • Research Site
      • Beijing, Beijing Municipality, China, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Research Site
      • Guangzhou, Guangdong, China, 510180
        • Research Site
      • Guangzhou, Guangdong, China, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, China, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, China, 450003
        • Research Site
      • Zhengzhou, Henan, China, 450052
        • Research Site
      • Zhengzhou, Henan, China, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Research Site
      • Wuhan, Hubei, China, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, China, 410008
        • Research Site
      • Changsha, Hunan, China, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Research Site
      • Nantong, Jiangsu, China, 226001
        • Research Site
      • Xuzhou, Jiangsu, China, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Research Site
      • Nanchang, Jiangxi, China, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, China, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, China, 250000
        • Research Site
      • Qingdao, Shandong, China, 266000
        • Research Site
      • Zibo, Shandong, China, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, China, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, China, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, China, 030000
        • Research Site
      • Xi’an, Shanxi, China, 710061
        • Research Site
      • Xi’an, Shanxi, China, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Research Site
      • Chengdu, Sichuan, China, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, China, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, China, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, China, 650034
        • Research Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Descrição

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Prazo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Prazo: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Prazo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Prazo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Prazo: 12 months

To characterize the progression of PNH

12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number and percentage of patients with each symptom of interest within follow-up
Prazo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Prazo: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Prazo: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Prazo: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Prazo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Prazo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Prazo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Prazo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Prazo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Prazo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Prazo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Prazo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Prazo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de novembro de 2023

Conclusão Primária (Real)

3 de dezembro de 2025

Conclusão do estudo (Real)

3 de dezembro de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

30 de outubro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de novembro de 2023

Primeira postagem (Real)

4 de dezembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

24 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • D7414R00001

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Prazo de Compartilhamento de IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critérios de acesso de compartilhamento IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .